|
| Abraxis Bioscience, Inc., a biotechnology company, delivers therapeutics and core technologies that offer patients and medical professionals treatments for cancer and other critical illnesses. It primarily focuses on an array of oncology drug candidates and a cardiovascular portfolio. The Abraxis portfolio includes protein-based nanoparticle chemotherapeutic compound, ABRAXANE, which is based on its proprietary tumor targeting system, known as the nab technology platform. The company also develops a pipeline, which includes further investigation with ABRAXANE, as well as other drug candidates. Its other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of solid tumors; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of solid tumors; and Coroxane for the treatment of coronary artery restenosisis. The company is headquartered in Los Angeles, California. |
- Premarket, intraday, nightly, and weekend updates, which include stock picks with full instructions, market direction (short, intermediate, long term), precious metal, commodity, and currency analysis.
- Provide you stock picks (breakouts) and market direction to help you become
more profitable.
- Voice over chart updates sent to you by e-mail. These updates contain stock picks and market status for a number of different portfolios, which Trending123 is recommending and following.
- Instantaneous e-mail alerts during the trading day when targets have been hit or the status of a position or the market warrants a move. Stock Recommendations for swing traders, day traders, and long term investors.
- Receive instant emails to your computer, organizer, cell phone of breakouts on stocks.....Learn More
|
|
|